Btk inhibitors, such as PRN2246 and evobrutinib, reduce inflammation by inhibiting activation of NLRP3 inflammasomes or NF-kB, both of which are implicated in MS pathology. This evidence concerns the gene NFKB1 and myeloid sarcoma.